Qlife Holding AB (OSTO:QLIFE) Long-Term Debt: kr8.35 Mil (As of Mar. 2026)


OSTO:QLIFE Qlife Holding AB OSTO:QLIFE
18 GF Score
Price kr1.81
GF Value kr0.75
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Qlife Holding AB Long-Term Debt?

Qlife Holding AB OSTO:QLIFE +2.96% 18 Long-Term Debt is kr8.35 Mil as of Mar. 2026. GuruFocus rates OSTO:QLIFE with a GF Score™ of 18/100 and a GF Value™ of kr0.75 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Qlife Holding AB's Long-Term Debt for the quarter that ended in Mar. 2026 was kr8.35 Mil.

Qlife Holding AB's quarterly Long-Term Debt declined from Sep. 2025 (kr8.55 Mil) to Dec. 2025 (kr8.13 Mil) but then increased from Dec. 2025 (kr8.13 Mil) to Mar. 2026 (kr8.35 Mil).

Qlife Holding AB's annual Long-Term Debt increased from Dec. 2023 (kr3.00 Mil) to Dec. 2024 (kr8.70 Mil) but then declined from Dec. 2024 (kr8.70 Mil) to Dec. 2025 (kr8.13 Mil).

Qlife Holding AB  (OSTO:QLIFE) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Qlife Holding AB Long-Term Debt Related Terms

Qlife Holding AB Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Qlife Holding AB's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qlife Holding AB Long-Term Debt Chart

Qlife Holding AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 2.76 3.01 3.00 8.70 8.13

Qlife Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.70 8.70 8.55 8.13 8.35
OSTO:QLIFE
18GF Score
Qlife Holding AB OSTO:QLIFE
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of kr8.35 Mil mean?
Qlife Holding AB (OSTO:QLIFE) has a Long-Term Debt of kr8.35 Mil as of Mar. 2026.
Is Qlife Holding AB's Long-Term Debt too high?
Qlife Holding AB's current Long-Term Debt is kr8.35 Mil. Overall, Qlife Holding AB has a GF Score™ of 18/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Qlife Holding AB's Long-Term Debt compare to ABT and SYK?
Qlife Holding AB's Long-Term Debt of kr8.35 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Qlife Holding AB's current Long-Term Debt is kr8.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qlife Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Qlife Holding AB (OSTO:QLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.75, compared to a current price of kr1.81 — trading 141.1% above its estimated fair value. The current Long-Term Debt is kr8.35 Mil. Qlife Holding AB's overall GF Score™ is 18/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Qlife Holding AB (OSTO:QLIFE), the current Long-Term Debt is kr8.35 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Qlife Holding AB (OSTO:QLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, Qlife Holding AB stock appears to be overvalued. The current stock price of kr1.81 is trading 141.1% above its estimated GF Value™ of kr0.75. GuruFocus considers Qlife Holding AB to be Significantly Overvalued.

Key valuation signals for OSTO:QLIFE:

  • Long-Term Debt: kr8.35 Mil
  • GF Value™: kr0.75 vs. price of kr1.81 (141.1% above fair value)
  • GF Score™: 18/100 with 9 warning signs

No single metric tells the full story. See the OSTO:QLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Qlife Holding AB Business Description

Other Exchanges 4HG0:Germany
Address Nellikevagen 22, Goteborg, SWE, SE-412 63
Qlife Holding AB is a medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it. The Egoo Home System is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient's doctor, clinic or hospital via smartphone and computer.
18GF Score

Get the complete analysis for OSTO:QLIFE

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.81
Price
kr0.75
GF Value